Why the study?
Anthracycline use is limited by dose-dependent cardiotoxicity, and a full understanding of its mechanisms is needed to advance effective detection, treatment, and cardioprotection strategies.
This review summarizes the current understanding of the mechanisms, monitoring, and prevention of anthracycline-induced cardiotoxicity.
Guides clinical monitoring and prevention of anthracycline cardiotoxicity; leaves open optimal strategies pending prospective validation.
Anthracyclines are the most fundamental and important treatment of several cancers especially for lymphoma and breast cancer. However, their use is limited by a dose-dependent cardiotoxicity which may emerge early at the initiation of anthracycline administration or several years after termination of the therapy. A full comprehending of the mechanisms of anthracycline-induced cardiotoxicity, which has not been achieved and is currently under the efforts, is critical to the advance of developing effective methods to protect against the cardiotoxicity, as well as to early detect and treat it. Therefore, we review the recent progress of the mechanism underlying anthracycline-induced cardiotoxicity, as well as approaches to monitor and prevent this issue.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: